Verzenio (abemaciclib)

pCPA File Number: 22038
Negotiation Status:
Under consideration for negotiation
Indication(s):
in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ≥20%
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CADTH Project Number:
PC0282
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable